Les résultats et les conclusions des travaux menés par l’écosystème Experts Recherche Lymphome sont publiés dans des journaux médicaux de premier plan.
Lysa
2020_LYSA_Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group
Hematol Oncol . 2020 Oct;38(4):446-455. doi: 10.1002/hon.2750.
En savoir plus
Lysa
2020_LYSA_Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T 3 phase IB trial of the LYSA
Ann Hematol . 2020 Aug;99(8):1771-1778. doi: 10.1007/s00277-020-04159-3.
En savoir plus
Lysa
2020_LYSA_Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study
Blood Adv . 2020 Aug 11;4(14):3217-3223. doi: 10.1182/bloodadvances.2020001955.
En savoir plus
Lysa
2020_LYSA_Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network
Eur J Nucl Med Mol Imaging . 2020 Oct 24. doi: 10.1007/s00259-020-05080-7
En savoir plus
Lysa
2020_LYSA_Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group
https://doi.org/10.1016/S2352-3026(20)30291-X
En savoir plus
Lysa
2020_LYSA_Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
https://doi.org/10.1016/S1470-2045(20)30441-1
En savoir plus
Lysa
2020_LYSA_Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA
Blood. 2020 Nov 19;blood.2020008750. doi: 10.1182/blood.2020008750
En savoir plus
Lysa
2020_LYSA_Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
Ann Oncol . 2020 Dec 2;S0923-7534(20)43174-6. doi: 10.1016/j.annonc.2020.11.019.
En savoir plus
Lysa
2020_LYSA_Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Blood Adv . 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001.
En savoir plus
Calym
2017_RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.
2017. Jun 2;45(10):5639-5652.
En savoir plus
Calym
2019_Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner.
Nat Commun, 10, 910.
En savoir plus
Calym
2017_Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell.
2017. Jun 2;45(10):5639-5652.
En savoir plus